NVLX PR: "successful Phase 1/2 clinical trials in advanced, inoperable pancreatic cancer already conducted using this technology. Nuvilex's rights to use this technology for the development of treatments for cancer were acquired from SG Austria and the license for its use in diabetes was acquired by Nuvilex from Austrianova Singapore. Importantly, Drs. Gunzburg and Salmons will continue to work closely with Nuvilex in projects that involve the use of this technology as Nuvilex prepares for and conducts its late-stage clinical trials."
(0)
(0)